X-Linked Severe Combined Immunodeficiency (X-SCID) Market Share Analysis, Growth Opportunities and Challenges, Treatment Algorithm, Emerging Pipeline Therapies, Epidemiology Insights

Posted on
by

X-Linked Severe Combined Immunodeficiency (X-SCID) Market Share Analysis, Growth Opportunities and Challenges, Treatment Algorithm, Emerging Pipeline Therapies, Epidemiology Insights
DelveInsight’s “X-Linked Severe Combined Immunodeficiency (X-SCID) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the X-Linked Severe Combined Immunodeficiency (X-SCID), historical and forecasted epidemiology as well as the X-Linked Severe Combined Immunodeficiency (X-SCID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “X-Linked Severe Combined Immunodeficiency (X-SCID) Market Insights, Epidemiology, and Market Forecast-2032”. 

 

DelveInsight’s “X-Linked Severe Combined Immunodeficiency (X-SCID) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the X-Linked Severe Combined Immunodeficiency (X-SCID), historical and forecasted epidemiology as well as the X-Linked Severe Combined Immunodeficiency (X-SCID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the X-Linked Severe Combined Immunodeficiency (X-SCID) Market Report: 

  • As per the Immune Deficiency Foundation 2019, The most common form of SCID, affecting nearly 45% of all cases, is due to a mutation in a gene on the X chromosome that encodes a component (or chain) shared by the T-cell growth factor receptor and other growth factor receptors 
  • Graphical Representation of X-Linked Severe Combined Immunodeficiency Epidemiology
  • Incident Cases of X-Linked Severe Combined Immunodeficiency in the 7MM 
  • X-linked Severe Combined Immunodeficiency (X-SCID) disorder is a fatal disease, without any curative therapy approved to date. The current goals of treatment include prophylaxis for infections and preemptive bone marrow transplant (BMT) prior to the development of symptoms 
  • The only treatment for X-linked SCID available at present is Bone Marrow Transplant (BMT). The temporary management of the disease involves the treatment of infections using Immunoglobulins and antibiotics 
  • The focus of the Researchers is mainly on development of Gene therapy for the treatment of X-Linked SCID

 

Request a sample for the Report: https://www.delveinsight.com/sample-request/xlinked-severe-combined-immunodeficiency-scid-market

 

Key benefits of the report:

  1. X-Linked Severe Combined Immunodeficiency (X-SCID) market report covers a descriptive overview and comprehensive insight of the X-Linked Severe Combined Immunodeficiency (X-SCID) Epidemiology and X-Linked Severe Combined Immunodeficiency (X-SCID)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The X-Linked Severe Combined Immunodeficiency (X-SCID) market report provides insights on the current and emerging therapies.
  3. X-Linked Severe Combined Immunodeficiency (X-SCID) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The X-Linked Severe Combined Immunodeficiency (X-SCID) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the X-Linked Severe Combined Immunodeficiency (X-SCID) market. 

 

Got queries? Click here to know more about the X-Linked Severe Combined Immunodeficiency (X-SCID) Market Landscape 

 

X-Linked Severe Combined Immunodeficiency (X-SCID) Overview: 

X-linked severe combined immunodeficiency (X-SCID) is an inherited disorder of the immune system that occurs almost exclusively in males. Boys with X-linked SCID are prone to recurrent and persistent infections because they lack the necessary immune cells to fight off certain bacteria, viruses, and fungi. Many infants with X-linked SCID develop chronic diarrhea, a fungal infection called thrush, and skin rashes. Affected individuals also grow more slowly than other children. Without treatment, males with X-linked SCID usually do not live beyond infancy. 

Mutations in the IL2RG gene cause X-linked SCID. The IL2RG gene provides instructions for making a protein that is critical for normal immune system function. This protein is necessary for the growth and maturation of developing immune system cells called lymphocytes. Lymphocytes defend the body against potentially harmful invaders, make antibodies, and help regulate the entire immune system. Mutations in the IL2RG gene prevent these cells from developing and functioning normally. Without functional lymphocytes, the body is unable to fight off infections. 

 

X-Linked Severe Combined Immunodeficiency (X-SCID) Symptoms:

The symptoms of X-Linked Severe Combined Immunodeficiency (X-SCID) include –

  • Oral/diaper candidiasis
  • Absent tonsils and lymph nodes
  • Rashes
  • Diarrhea
  • High Fever
  • Pneumonia

 

Epidemiology Segmentation of X-Linked Severe Combined Immunodeficiency:

  • Prevalent Cases of X-Linked Severe Combined Immunodeficiency in the 7MM [2019-2032]
  • Age-Specific Cases of X-Linked Severe Combined Immunodeficiency in the 7MM [2019–2032]
  • Gender-Specific Cases of X-Linked Severe Combined Immunodeficiency in the 7MM [2019–2032]
  • Diagnosed and Treated Cases of X-Linked Severe Combined Immunodeficiency in the 7MM [2019–2032]

 

X-Linked Severe Combined Immunodeficiency (X-SCID) Market 

The dynamics of the X-Linked Severe Combined Immunodeficiency (X-SCID) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Palifermin, Busulfan, and others during the forecasted period 2019-2032. 

 

Learn more by requesting for sample @X-Linked Severe Combined Immunodeficiency (X-SCID) Market Landscape 

 

X-Linked Severe Combined Immunodeficiency (X-SCID) Pipeline Therapies: 

  • Palifermin
  • Busulfan
  • Increlex
  • Gene-Transduced Autologous 

 

X-Linked Severe Combined Immunodeficiency (X-SCID) Pipeline Key Companies:

  • National Institutes of Health Clinical Center (CC)
  • National Institute of Allergy and Infectious Diseases (NIAID) 

 

Table of Contents 

1. X-Linked Severe Combined Immunodeficiency (X-SCID) Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. X-Linked Severe Combined Immunodeficiency (X-SCID) Patient Share (%) Overview at a Glance

5. X-Linked Severe Combined Immunodeficiency (X-SCID) Market Overview at a Glance

6. X-Linked Severe Combined Immunodeficiency (X-SCID) Disease Background and Overview

7. X-Linked Severe Combined Immunodeficiency (X-SCID) Epidemiology and Patient Population

8. Country-Specific Patient Population of X-Linked Severe Combined Immunodeficiency (X-SCID) 

9. X-Linked Severe Combined Immunodeficiency (X-SCID) Current Treatment and Medical Practices

10. X-Linked Severe Combined Immunodeficiency (X-SCID) Unmet Needs

11. X-Linked Severe Combined Immunodeficiency (X-SCID) Emerging Therapies

12. X-Linked Severe Combined Immunodeficiency (X-SCID) Market Outlook

13. Country-Wise X-Linked Severe Combined Immunodeficiency (X-SCID) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. X-Linked Severe Combined Immunodeficiency (X-SCID) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

Click here to read more about X-Linked Severe Combined Immunodeficiency (X-SCID) Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com